ESMO Virtual Advanced Course on Clinical Questions in Prostate Cancer

Programme

ESMO VIRTUAL
ADVANCED COURSE

9-10 DECEMBER 2021

Co-Chairs
Gerhardt Attard, United Kingdom
Ravindran Kanesvaran, Singapore
ESMO VIRTUAL ADVANCED COURSE PROGRAMME

CLINICAL QUESTIONS IN PROSTATE CANCER

9-10 December 2021

CO-CHAIRS: Gerhardt Attard, United Kingdom
               Ravindran Kanesvaran, Singapore

SPEAKERS: Arun Azad, Australia
          Elena Castro Marcos, Spain
          Melvin Lee Kiang Chua, Singapore
          Darren M.C. Poon, Hong Kong
          Sue Ping Thang, Singapore

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
- To learn about state-of-the-art advances in treatment of prostate cancer
- To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios

ACCREDITATION

The programme of this event has been accredited with 6 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

astellas

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
All timings are to be considered GMT+8 (Singapore Local Time)

Thursday, 9 December 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00-15:05</td>
<td>Welcome and course overview</td>
<td>Gerhardt Attard, UK, Ravindran Kanesvaran, SG</td>
</tr>
<tr>
<td>15:05-15:45</td>
<td>Session 1</td>
<td>State-of-the-art in prostate cancer diagnostics (Chair/Moderator: Ravindran Kanesvaran, SG)</td>
</tr>
<tr>
<td>15'</td>
<td>PSMA based diagnostics: The future of imaging</td>
<td>Sue Ping Thang, SG</td>
</tr>
<tr>
<td>15'</td>
<td>Updates in biology: Clinical genomics in prostate cancer management</td>
<td>Elena Castro Marcos, ES</td>
</tr>
<tr>
<td>10'</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>15:45-15:55</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:55-16:35</td>
<td>Session 2</td>
<td>High risk localized prostate cancer (Chair/Moderator: Gerhardt Attard, UK)</td>
</tr>
<tr>
<td>15'</td>
<td>Role of radiotherapy: Recent advances in RT modalities <em>(including hypofractionation, brachytherapy, SABR)</em></td>
<td>Melvin Lee Kiang Chua, SG</td>
</tr>
<tr>
<td>15'</td>
<td>High risk localized disease: Integrating systemic therapy with local treatments</td>
<td>Darren M.C. Poon, HK</td>
</tr>
<tr>
<td>10'</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>16:35-17:25</td>
<td>Session 3</td>
<td>Non metastatic / Oligometastatic advanced prostate cancer (Chair/Moderator: Ravindran Kanesvaran, SG)</td>
</tr>
<tr>
<td>15'</td>
<td>Rising PSA: nmHSPC</td>
<td>Darren M.C. Poon, HK</td>
</tr>
<tr>
<td>15'</td>
<td>Oligometastatic prostate cancer</td>
<td>Melvin Lee Kiang Chua, SG</td>
</tr>
</tbody>
</table>
10'  State-of-the-art management of M0 Castrate Resistant Prostate Cancer (CRPC)  
Arun Azad, AU

10'  Discussion  
Faculty

17:25-18:05  Session 4  
Metastatic prostate cancer — part 1 (Chair/Moderator: Gerhardt Attard, UK)

15'  Metastatic hormone sensitive prostate cancer: State of the art management in 2021  
Ravindran Kanesvaran, SG

15'  Metastatic CRPC: Standard of care in 2021 \( \textit{(including bone targeting agents)} \)  
Arun Azad, AU

10'  Discussion  
Faculty

Friday, 10 December 2021

15:00-15:25  Session 5  
Metastatic prostate cancer — part 2 (Chair/Moderator: Ravindran Kanesvaran, SG)

15'  Metastatic CRPC: What’s on the horizon — new treatments  
Gerhardt Attard, UK

10'  Discussion and summary  
Gerhardt Attard, UK  
Ravindran Kanesvaran, SG

15:25-17:35  Workshops sessions  
Three workshops sessions  
10’ Introduction based on clinical cases presented by speakers  
30’ Discussion

Workshop 1  
40’  Localized prostate cancer  
Darren M.C. Poon, HK  
Melvin Lee Kiang Chua, SG

16:05-16:15  Break
Workshop 2
Intermediate advanced prostate cancer
Ravindran Kanesvaran, SG
Arun Azad, AU

Workshop 3
Metastatic prostate cancer
Gerhardt Attard, UK
Elena Castro Marcos, ES

17:35–18:00 Feedback on the workshops

18:00–18:05 Synthesis and wrap-up
Gerhardt Attard, UK
Ravindran Kanesvaran, SG